Race affects SVR12 in a large and ethnically diverse hepatitis C-infected patient population following treatment with direct-acting antivirals: Analysis of a single-center Department of Veterans Affairs cohort. [PDF]
, 2018 Hepatitis C virus (HCV) infection is a major cause of chronic liver disease. HCV cure has been linked to improved patient outcomes. In the era of direct-acting antivirals (DAAs), HCV cure has become the goal, as defined by sustained virological response ...
Benhammou, Jihane N +9 more
core +1 more source
Emerging Infectious Diseases, 2022 Ribavirin has been used widely to treat Lassa fever in West Africa since the 1980s. However, few studies have systematically appraised the evidence for its use.
Hung-Yuan Cheng +8 more
doaj +1 more source
Virology Journal, 2011 Background Current standard therapy commonly followed for chronic Hepatitis C Virus (HCV) in Pakistan is interferon alpha plus ribavirin combination therapy (IFN α/ribavirin) and pegylated interferon plus ribavirin (PegIFN/ribavirin).
Saleem Sana +10 more
doaj +1 more source
Minimum target prices for production of direct acting antivirals and associated diagnostics to combat Hepatitis C Virus [PDF]
, 2014 Combinations of direct-acting antivirals (DAAs) can cure hepatitis C virus (HCV) in the majority of treatment-naïve patients. Mass treatment programs to cure HCV in developing countries are only feasible if the costs of treatment and laboratory ...
Cooke, GS +6 more
core +2 more sources
IDCases, 2023 Persistent Hepatitis E Virus infection (HEV) is a rare but increasingly recognised condition in immunocompromised individuals. Untreated, this infection can rapidly progress to cirrhosis.
Jennifer Gallacher +4 more
doaj +1 more source
Enhancement of Crystallization Process of the Organic Pharmaceutical Molecules through High Pressure
Crystals, 2022 The enhancement of the crystallization process through high pressures was studied by using ribavirin (RVB) as a model compound. The effects of high pressure on crystallization thermodynamics, nucleation kinetics, and process yield were evaluated and ...
Yaoguang Feng +5 more
doaj +1 more source
Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment [PDF]
, 2010 Background Early detection of nonresponders to hepatitis C therapy limits unnecessary exposure to treatment and its side-effects. A recent algorithm combining baseline anti-NS4a antibodies and on-treatment quantitative PCR identified nonresponders to a ...
de Knegt, Robert J +8 more
core +1 more source
Adding low-dose antidepressants to interferon alpha treatment for chronic hepatitis C improved psychiatric tolerability in a patient with schizoaffective psychosis [PDF]
, 2000 Treatment of chronic hepatitis C with interferon alpha (IFN-alpha) is relatively contraindicated in patients with psychiatric disorders because of possible severe psychiatric side effects.
Amann, B. +5 more
core +1 more source
Case Reports in Dermatology, 2013 The introduction of ribavirin to hepatitis C combination therapy with pegylated interferon (PEG-IFN)-α2a has improved sustained responses, but it has been accompanied by an increased incidence of cutaneous side effects. Most cases of drug eruption caused
Masahisa Shindo, Isamu Terai
doaj +1 more source
Evaluation of Ribavirin–Poloxamer Microparticles for Improved Intranasal Absorption
Pharmaceutics, 2021 Ribavirin is a water-soluble antiviral compound which, owing to its inability to cross the blood–brain barrier, has limited effectiveness in treating viruses affecting the central nervous system.
Dipy M. Vasa +4 more
doaj +1 more source